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Abstract
Background. – In France, the human papillomavirus vaccine is routinely recommended for 14-year-old females and a ‘‘catch-up’’ vaccination
should be offered to female adolescents who are between 15 and 23 years of age. Currently, few studies are available on the coverage rates in
France. The aim of this study was to evaluate the coverage of the human papillomavirus vaccine and compliance with the vaccination scheme in
Picardy, between 2009 and 2010, and to analyze the socioeconomic factors possibly influencing this coverage.
Methods. – We selected a female population that was affiliated with the national health insurance organization, living in the Picardy region of
France, and aged between 14 and 23 years on 31st December 2010.
Results. – The coverage rate in the study population with at least one dose of vaccine was 16.8%. A complete vaccination scheme (three doses)
was observed in less than 38.9% of them, so only 6.5% of this population had received the complete vaccination. Higher rates of coverage and
compliance were observed in girls 14 years of age (65.5%) and if the prescriber was a gynecologist or pediatrician (respectively, 44.7% and 48.1%).
There is a negative correlation between coverage and compliance and the percentage of single-parent families and immigrant families by canton
area of Picardy. The economic cost of an inappropriate scheme was 1.3 million euros for Picardy in 2009.
Conclusion. – Coverage and compliance rates of human papillomavirus vaccines in Picardy appear to be low. This study suggests that health
authorities in Picardy should provide communication and action campaigns to improve these results.
# 2013 Elsevier Masson SAS. All rights reserved.
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Re´sume´
Position du proble`me. – La vaccination contre le papillomavirus humain (HPV) est recommande´e en France depuis avril 2007 chez les jeunes filles
de 14 ans et en rattrapage chez les jeunes filles de 15 a` 23 ans, en pre´vention des cancers du col de l’ute´rus. Actuellement, peu de donne´es sur le taux de
couverture vaccinale en France sont disponibles. L’objectif de cette e´tude e´tait d’estimer le taux de couverture vaccinale en Picardie en 2009–2010,
l’observance du sche´ma vaccinal parmi les femmes ayant rec¸u au moins une dose et de de´terminer les facteurs socioe´conomiques jouant sur ce taux.
Me´thodes. – Il s’agit d’une e´tude re´trospective s’appuyant sur l’analyse des donne´es de remboursements des vaccins anti-HPV pour les jeunes
filles picardes aˆge´es de 14 a` 23 ans au moment de la de´livrance de la premie`re dose.
Re´sultats. – Dans la population d’e´tude, 16,8 % des affilie´es ont rec¸u au moins une dose vaccinale. Le taux de couverture vaccinale avec
sche´ma vaccinal complet a e´te´ estime´ a` 6,5 %. L’observance du sche´ma vaccinal e´tait meilleure si la jeune fille de´marrait la vaccination a` 14 ans
(65,5 %) et si le primo prescripteur e´tait un gyne´cologue-obste´tricien ou un pe´diatre (respectivement 44,7 % et 48,1 %). Il existe une corre´lation
ne´gative entre le taux de couverture vaccinale et le taux d’immigre´s et de familles monoparentales par canton. Le couˆt de la mauvaise observance
du sche´ma vaccinal a pu eˆtre chiffre´ a` plus de 1,3 millions d’euros pour la Picardie en 2009.
Conclusion. – Le taux de couverture vaccinal contre le HPVen Picardie est faible. Ce faible taux constitue une perte de chance tant individuelle
que collective. Ce travail souligne l’inte´reˆt de mener des actions avec les acteurs locaux afin d’ame´liorer ces re´sultats.
# 2013 Elsevier Masson SAS. Tous droits re´serve´s.
Mots cle´s : HPV ; Vaccination ; Adolescentes ; Facteurs socioe´conomiques ; Picardie
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In 2006, two prophylactic vaccines against human
papillomaviruses (HPV) obtained marketing approval by the
European Drug Agency (Agence europe´enne du me´dicament)
and have been put on the market. Gardasil1 (sold by Sanofi
Pasteur MSD) is a quadrivalent vaccine targeting the high-risk
genotypes 16 and 18 found in 70% of cervical cancers and the
low-risk genotypes 6 and 11 [1–7]. Cervarix1 (marketed by
GlaxoSmithKline) is a bivalent vaccine directed against
genotypes 16 and 18. These vaccines have demonstrated their
efficacy in preventing the onset of precancerous lesions of the
uterine cervix caused by HPV types 16 and/or 18 as well as
precancerous lesions of the vulva and external genital warts
caused by HPV type 6, 11, 16, and/or 18 [8–10].
In France, it is recommended to limit the use of these
vaccines to 14-year-old girls and use them as ‘‘catch-up’’ in 15-
to 23-year-old young women who have never had sexual
relations or at the latest 1 year after their first sexual relations.
The vaccination protocol providing maximum efficacy includes
three doses to be administered over a 6-month period [11–13].
However, the High Council for Public Health (Haut Conseil en
Sante´ Publique) has recently revised this recommendation and
advised that vaccination take place between 11 and 14 years of
age [14].
France has no organized HPV vaccination program.
Vaccination is therefore opportunistic and left to the initiative
of parents or the young women themselves. Yet it has been
shown that the epidemiological impact on uterine cervical
cancer is highly dependent on the level of vaccine coverage.
The only data that can currently be used to evaluate the
vaccination coverage in France are those from health insurance
information systems. These are data on the reimbursements for
the vaccines delivered to insured patients in pharmacies. Few
studies have been conducted in France to measure the rate of
vaccination coverage. Fagot et al. [15] showed that 37.5% of
14- to 23-year-old women had begun the vaccination in 2007–
2008. However, these results are very heterogeneous at the
national level: Rouzier showed that in Paris, between 2007 and
2009, only 17% of insured young women received a dose,
reporting a 43% compliance rate [16].
The objective of this study was to estimate the vaccination
coverage of young women in Picardy, France, for the 2009–
2010 period based on data from the reimbursements for vaccine
doses delivered and to study certain socioeconomic factors that
could be influential.
2. Methods
This was a retrospective study based on the analysis of
reimbursements for Gardasil1 and Cervarix1 vaccine reim-
bursements by the Re´gime Ge´ne´ral (health insurance
administration for employed personnel), the Re´gime Social
des Inde´pendants (health insurance administration for the
self-employed; RSI), and the Mutualite´ Sociale Agricole
(health insurance administration for agricultural occupations;
MSA) in Picardy, France. It examined all young women aged14–23 years at the time the first dose of the vaccine was
delivered, who were affiliated with one of the three health
insurance organizations and who had received the first vaccine
dose between 1st January 2009 and 31st December 2010. The
data were extracted from the Syste`me Informationnel de
l’Assurance Maladie (SIAM-ERASME Re´gional) of the
Caisse Re´gionale d’Assurance Maladie (national health
insurance organization; CRAM) in the Nord–Pas-de-Calais-
Picardie region and were completed by data from the Picardy
MSA and RSI information systems data. All young women
born between 1986 and 1996 who had been reimbursed for at
least one Gardasil1 or Cervarix1 dose between 1st January
2009 and 31st December 2010 were identified. The data
transmitted included information on the beneficiaries (ano-
nymous identity number, year of birth, residence canton code),
vaccine doses (CIP codes, delivery dates), and prescribers
(specialization). Additional data concerning the demography
of the female population belonging to one of the three health
insurance organizations on 1st January 2010 according to year
of birth were transmitted and the Service OSA (Observation,
Statistique et Analyse; Observation, Statistics, and Analysis)
of the Agence Re´gionale de Sante´ (regional healthcare agency;
ARS), which provided data on the demography of healthcare
professionals according to their specialization and the canton
in which they practiced. Four socioeconomic indicators were
collected for each canton from national data (INSEE): the
percentage of immigrants, the rate of single-parent families,
the median income per consumption unit, and the rate of
taxable households.
The rate of vaccination coverage by at least one dose was
defined as the number of young women who had received at
least one vaccine dose during the reference period, divided by
the number of young women born between 1986 and 1996
belonging to one of the three health insurance organizations on
1st January 2010.
As for compliance with the vaccine protocol, according to the
French Health Authority for Health Transparency Commission
(Commission de Transparence de la HAS) through a decree
passed on 18 April 2007 and 5 March 2008, a 3-year period for
the delivery of the three doses was chosen. Young women having
received the three doses or more in less than 1 year were therefore
considered compliant and the compliance rate was defined as the
number of women having received the three doses or more in less
than 1 year among those who received at least one dose. The
calculation of the compliance rate only took into account those
young women who began thevaccination in 2009 (without taking
into account those who began the vaccination in 2010), which
made it possible to partially control for a bias affecting the total
number of doses received.
In addition, the impact on compliance of the prescriber’s
specialization and the patient’s age at delivery of the first dose
were studied. We also examined whether the coverage rate by
canton was associated with the percentage of immigrants, the
single-parent family rate, median income, and the rate of
taxable households.
To calculate the cost of the vaccination, we took into account
the price of the vaccine doses (123.66 s for Gardasil1 and
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the price of the physician consultations (consultation at 23 s
including the clinical and technical act), considering that one
consultation was necessary for each dose delivered. The cost for
the national health insurance system was calculated considering
that each vaccine dose was reimbursed based on 65% of the
retail price and that each consultation was reimbursed at a rate
of 70% of the statutory fee. The cost of poor compliance was
assessed considering that young women who had received one,
two, or three doses but within more than 1 year were not
properly immunized according to the HAS guidelines. Finally,
for young women who received more than three doses, the
number of doses beyond three was counted. The cost of each
dose ‘‘lost’’ or delivered in excess was added to the fee of a
physician’s consultation.
3. Statistical analysis
The quantitative data were expressed as the mean and
standard deviation and the qualitative data in absolute numbers
and percentages. The coverage and compliance rates were
compared using the x2 or the Fisher exact test as needed.
The association between the vaccination coverage and/or
compliance rates and the socioeconomic indicators was
estimated using the Pearson correlation coefficient. A P-value
less than 0.05 was considered significant. The analyses were
done using SPSS11.0 and R software.
4. Results
During the study period, the female population affiliated
with one of the three health insurance programs in Picardy
included 138,042 individuals aged from 14 to 23 years. In this
population, 23,139 individuals received at least one vaccine
dose between 1st January 2009 and 1st January 2011 (16.8%).
During this period, 45,915 vaccine doses were delivered:
25,600 in 2009 and 20,315 in 2010, a 20.6% decrease. The
monthly number of vaccine doses delivered declined regularly
from January 2009 to December 2010, decreasing from 2576
doses delivered in January 2009 to 1554 in December 2010
(Fig. 1). The majority of these doses (92%) were prescribed by2576
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Fig. 1. Number of doses delivered monthlygeneral practitioners. Obstetricians were the second providers
of vaccine prescriptions (3.3% of the doses prescribed),
followed by pediatricians (2.1%) and gynecologists (1.9%).
Gynecologists in Picardy had prescribed a mean 26 doses per
practitioner in 2 years, slightly more than general practitioners
(25 doses per practitioner in 2 years), whereas obstetricians and
pediatricians had prescribed 17 and 16 doses, respectively, per
practitioner in 2 years. Over the entire 2-year period, 95.5% of
the doses delivered were Gardasil1 and 4.5% Cervarix1.
The rate of vaccine coverage by at least one dose was highest
in the Aisne department (17.7% the individuals affiliated with a
health insurance organization) and the lowest in the Oise
department (16.0% of the affiliated members). Substantial
discrepancies in vaccine coverage were noted between cantons,
with the rate ranging from 4.7% (Breteuil canton, Oise) to 25.9%
(Abbeville Nord canton, Somme) (Fig. 2). Young women
affiliated with the MSA had a higher rate of vaccine coverage by
at least one dose than the mean rate (22.1%), and women
affiliated with the RSI had a lower vaccine coverage rate (14.6%)
than the mean and a lower rate than that recorded for women
affiliated with the Re´gime Ge´ne´ral (16.7%) (P = 0.0001). One-
quarter of patients (25.8% of the patients who had received at
least one dose) were 15 years old at the time the first dose was
delivered. Those who were 14 years old when the first dose was
delivered (target population) made up a smaller proportion
(22.3%) (Fig. 3). Between 2009 and 2010, we observed a 57%
decrease in the number of young women aged 15–23 years at the
time the first dose was delivered. This number decreased from
12,479 to 5415. Within the entire sample of women who had
begun the vaccination in 2009, 58% had not followed the
complete vaccination protocol and 3.1% had received the three
doses, but over more than 1 year. Consequently, 61.1% of the
young women in Picardy who had begun vaccination were not
properly immunized. The young women living in the Aisne and
Oise departments were the least compliant: 38.0% versus 40.3%
in the Somme department. Significant discrepancies between
cantons can be noted, with rates ranging from 22.4% (in the
Compie`gne Sud-Ouest canton) to 83.3% (in the Breteuil canton).
The rate of vaccination coverage with the complete protocol was
estimated for Picardy at 6.5% in 24 months, and few differences
were observed in the three departments, but here also a difference1520
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 during the study period (2009–2010).
Fig. 2. Vaccination coverage (at least one dose) per canton in the Picardy region.
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3.5% (Combles canton) to 13.0% (Abbeville Sud canton).
The young women affiliated with the RSI were the most
compliant (54.8% of those having received at least one vaccine
dose had received the three in less than 1 year). Those affiliated
with the RSA had a lower compliance rate (45.4%), but it was
higher than those affiliated with the Re´gime Ge´ne´ral (38.2%).
The differences observed between health insurance organiza-
tions were statistically significant (P < 0.001).
The most compliant young women were those aged 14 years
when the first dose was delivered (65.5%). In the population
concerned by ‘‘catch-up’’ vaccination, the most observant were
those at 15 years of age when the first dose was delivered
(43.1%). For the 14- to 23-year olds who had begun vaccination
in 2009 or 2010, the compliance rate was estimated at 38.9%.0.3%
22.3%
25.8%
16.2%
13.6%
9.3%
13y 14 y 15 y 16 y 17 y 18 y 
Fig. 3. Distribution of affiliated members who received aThe vaccine coverage rate was highest for those born in 1995
(26.7% of the affiliated members). Those born in 1996 had a
lower vaccination coverage rate (10.2%). In the population
using ‘‘catch-up’’ vaccination, the coverage rate was highest in
women born in 1994 (17.3%). It then decreased exponentially
to reach 0.4% in women born in 1986.
Compliance of the vaccination scheme also differed
depending on the specialization of the physician prescribing
the first dose. If a general practitioner had prescribed the first
vaccine dose, 38.3% having received the first dose received
three doses within less than 1 year. If the first prescriber was a
pediatrician or an obstetrician, these percentages were 48.1%
and 44.7%, respectively (P < 0.001).
As for the investigation of factors that may influence the
vaccination and compliance rate, a statistically significant5.2%
2.9%
1.8% 1.4% 1.1%
0.0%
19y 20 y 21 y 22 y 23 y 24 y
t least one dose by age of delivery of the first dose.
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Fig. 4. Correlation between vaccination rate (at least one dose) and the rate of immigrants by canton in Picardy.
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immigrants per canton and vaccination (R2 = 0.06; P = 0.007).
There was also a statistically significant negative correlation with
the rate of single-parent families per canton (R2 = 0.08;
P = 0.002). (Figs. 4 and 5). These negative correlations were
also observed in the Somme and Aisne departments, but not in the
Oise department.
As for the socioeconomic factors, no correlation between
vaccination coverage, median income per consumption unit,
and the percentage of taxable households was found (P = 0.6
and P = 0.8, respectively). The same factors as those related to
vaccination coverage by at least one dose were found to be
associated with complete vaccination coverage: the rate of
immigrants (R2 = 0.1; P < 0.001) and the rate of single-parent
families (R2 = 0.12; P < 0.001).
Vaccination of young women in Picardy in 2009 and 2010
cost the national health insurance approximately 4.4 million
euros: 3.7 million euros for the cost of the vaccine doses (83%
of the total expenditure). Poor compliance with the vaccination
protocol was a substantial financial loss: 1.3 million euros in
2009 for young women in Picardy. This sum for the most part
involves the cost of the vaccine doses (approximately 1.1
million euros for more than 13,500 doses).
5. Discussion
HPV vaccination coverage is low in Picardy, since only
16.8% of 14- to 23-year-old women had received at least oneFig. 5. Correlation between vaccination rate (at least one dose) vaccine dose and only 6.5% had received the complete vaccine
protocol. In the target population (14-year-old females in 2009
or 2010), approximately one out of three (32.3%) began
vaccination, and the complete vaccination coverage of this
target population is estimated at 18.5%. For the most part,
young women in Picardy begin vaccination at 15 years of age,
which does not correspond stricto sensu to the guidelines.
However, a slight progression in beginning the vaccination
between 2009 and 2010 (+12%) was noted for 14-year-old
females. A study on the period ranging from July 2007 to
August 2009 in those affiliated with Re´gime Ge´ne´ral found for
Picardy a 26% vaccination coverage rate, and 40% for 14-year-
old in 2008 [15].
One problem raised by HPV vaccination is compliance with
the vaccine protocol, since only 38.9% of the young women
who began vaccination received three doses in less than 1 year.
This problem is all the more preoccupying in that compliance
seems to decrease over time. The study reported by Fagot et al.
found 71% compliance for those affiliated with the Re´gime
Ge´ne´ral and 75% of 14-year-old affiliated members in 2008
[15]. Three other studies were conducted in Paris on the period
from July 2007 to April 2009 [16], in the Nord–Pas-de-Calais
region for the period extending from July 2007 to May 2009
[17] and in the Franche-Comte´ region for 2009 and 2010 [18].
In Paris, 17% of the members received at least one dose
between July 2007 and April 2009, which is comparable to the
situation in Picardy for the 2009–2010 period. The compliance
rate for young Parisian women was 43%, comparable to thoseand the rate of single-parent families by canton in Picardy.
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affiliated members 14 years of age and 59.8% of those 15 years
of age received a first vaccine dose at this age. The compliance
rate was 63.6% [17]. Young women in Picardy are therefore less
well covered than their neighboring counterparts by the HPV
vaccine. Fewer of them start the vaccination and compliance
with the vaccine scheme is lower. Finally, in the Franche-Comte´
region, 11.3% of 14- to 23-year-old young women started
vaccination (compared to 16.8% in Picardy) with a 32%
compliance rate, a complete vaccination coverage rate of 3.6%,
lower than that in Picardy [18].
The three-dose vaccination protocol must be respected even
if the third dose is administered beyond 12 months after the first
dose [14]. For the moment, few studies can justify a two-dose
vaccination protocol. A study conducted in Costa Rica suggests
that individuals who are vaccinated with fewer than three
bivalent vaccine doses have comparable protection [14,19]. As
for 14-year-old affiliated individuals, 29.7% of them started
vaccination, with a 43.2% compliance rate and 51.3% for the
2009 and 2010 cohorts, respectively, for a 21% vaccination
coverage rate. These results are disappointing, particularly
since the importance of high vaccination coverage for a
significant epidemiological impact on uterine cervical cancer
has been underscored [20].
Two consequences result from poor compliance with the
vaccination protocol: young women are not properly immunized
and the cost for the national health insurance program is high
(approximately 1.3 million euros per year). This financial loss
corresponds to the costs of vaccination of slightly more than one-
third of the population of 14-year-old females in Picardy in a
given year (theoretical total cost, 3.4 million euros).
Several factors influencing compliance have been reported in
the literature [21–26]. Two factors have been identified in the
present study. First of all, the patient’s age at the time the first
dose is delivered: young 13- or 14-year-old are more compliant
than their older peers (64.8% vs 33.6%). In addition, among the
15- to 23-year-old young women, those who are 15-years-old
when the first dose is delivered respect the vaccination protocol
more closely. These data are identical to those found in the
literature [16]. At this age, young women are probably still
accompanied by their mothers to medical consultations. It can be
assumed that mothers are more vigilant in terms of respecting the
vaccination protocol once the vaccination has been started. The
other factor identified is the specialization of the prescribing
physician. When the vaccine doses were prescribed by a
specialist (notably a pediatrician or a gynecologist), a larger
number of the young women received the three doses (48.1% and
44.7% for pediatricians and gynecologists, respectively, versus
38.3% for GPs) [27].
This study has demonstrated the discrepancies between
departments in France in terms of HPV vaccination coverage.
We found higher coverage rates in the Somme than in Aisne and
Oise departments. We also noted discrepancies related to the
young women’s health insurance sector affiliation. The RSI and
the MSA recorded better vaccination coverage for their
members than the Re´gime Ge´ne´ral. Information campaigns
for each of these sections may be the source of the better results.As for the specialization of the prescribing physician, nearly
92% of the doses are prescribed by general practitioners.
Analysis of the number of doses prescribed per practitioner
showed that gynecologists, specialists who are undoubtedly
more aware of the problem of uterine cervix cancer, had on
average prescribed a higher number of doses (26 doses per
practitioner in 2 years) than GPs (25 doses per practitioner in
2 years) [27].
There are currently few studies on the socioeconomic
determinants of vaccination coverage. The results found in the
literature argue in favor of better vaccination coverage in high-
income populations [16]. Studies on social inequalities in
healthcare have shown lower access to prevention and primary
medical care, and lower adherence to treatment for socially
underprivileged populations [28]. However, the socioeconomic
situation is not the only explanation. Studies on the acceptability
of HPV vaccination demonstrate the role played by knowledge
and beliefs [21]. Women and young women who are poorly
informed on the causes of cervical cancer and prevention are less
likely to get vaccinated [22]. In addition, improving knowledge
on vaccination increases acceptability [23]. Concerning beliefs,
the intention to get vaccinated is higher in individuals convinced
of the vaccine’s efficacy [21], but the fear of its side effects may
be the reason for deciding against it [24]. The question of the role
played by the opinion of physicians who prescribe these vaccines
should also be raised. It seems probable that a physician opposed
to HPV vaccination will be reluctant to prescribe it for his or her
patients. A study on the perception of the HPV vaccine in general
medicine conducted in the Somme department found among the
obstacles to prescribing the vaccine the lack of perspective on the
efficacy and the potential side effects, the fear of increasing risky
sexual behavior, the fear of decreasing screening in vaccinated
patients, and the reluctance to bring up questions of sexuality in
young patients [29]. A study conducted in the Rhoˆne-Alpes
region on gynecologists found the same results [27].
Significant negative correlations were observed between the
vaccination coverage rate and the rate of immigrants per canton
as well as between the vaccination coverage rate and the rate of
single-parent families. These factors seem to be related,
without it being possible to deduce a cause and effect
relationship. However, it can be assumed that the cultural
factor is a major determinant in the acceptance of the
vaccination, which could explain the relation found between
the rate of immigrants and the vaccination coverage rate. The
socioprofessional level of these populations may also be an
explanatory factor. On the other hand, the median income per
consumption unit and the rate of taxable households was not
correlated with the vaccination coverage rate. The financial
factor does not seem to be determinant in this study, but it
should be remembered that this is an ecological correlation
study at the canton level and that this type of correlation cannot
be interpreted as causality (or an absence of causality) on an
individual level. Rouzier and Giordanella demonstrated a
positive correlation between the median per capita income by
arrondissement and the vaccination coverage rate [16].
Similarly, Baudu’s study found a positive significant associa-
tion between the rate of vaccinated individuals per canton and
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limit of significance for median income in the Haute-Saoˆne
department. On the other hand, this study did not demonstrate a
correlation between vaccination coverage and immigration
[18]. It should be remembered that for an individual who did not
have supplementary insurance beyond national health insu-
rance coverage, the cost of the vaccination left to pay was
approximately 150 s.
This study has a number of limits related to the type of data
used. The data recorded in the databases of the National Health
Insurance are intended to estimate the costs of healthcare
services and healthcare products consumed by the beneficiaries
and not to conduct epidemiological studies. We therefore
hypothesized that each dose delivered was administered. Yet a
certain number of members received more than three doses (up to
six doses delivered). This may be an error of identification of the
beneficiary on the part of the pharmacist for those entitled to
healthcare coverage but do not have their own social security
number (e.g., attribution to a sister), but this may also be
individuals for whom the dose or doses may have been delivered
but not administered. However, the number of affiliated members
who received more than three doses was limited (approximately
1.5% of the members who had received at least one dose). In
addition, this study only took into account the doses prescribed
by private practitioners. The doses delivered in healthcare centers
or at hospitals were not counted. However, the majority of the
doses were prescribed by GPs; consequently, this number can be
considered negligible.
In addition, the data concerned the population covered by one
of the three main health insurance programs (Re´gime Ge´ne´ral,
RSI, or MSA), approximately 85% of the population. It did not
cover the young women affiliated with special systems, notably
those covered by the student health insurance. The 18- to 23-
year-old population of affiliated members compiled was not as
exhaustive as the 14- to 17-year-old population.
Compliance with the vaccination protocol is probably
slightly underestimated in this work. Young women who began
the vaccination in 2008 may appear in our database if they
completed the protocol in 2009, but in this case they appear
among the affiliated members who received only one or two
vaccine doses, thus biasing the estimation of compliance. The
problem was neutralized on the other side of the interval
(patients who began vaccination in 2010) in only taking into
account the young women who had begun vaccination in 2009
for the compliance calculation.
6. Conclusion
HPV vaccination coverage in Picardy in 2009–2010 is low
and continues to decrease compared to 2008. Compliance with
the vaccination protocol is mediocre, resulting in a substantial
financial loss for the National Health Insurance and a loss of
opportunity for the young women concerned and for the entire
population. Compliance is better if the young woman begins
vaccination early. This observation is valuable in future attempts
to improve vaccination coverage by lowering the vaccination
age. This is already current practice in several Europeancountries that recommend beginning vaccination at 12 years of
age. The different cultural and sociodemographic components
that can play a role in the participation rate and the compliance
rate for this vaccination should also be taken into account.
The arrival of vaccination may raise the fear of less use of
screening measures for cervical cancer in young vaccinated
women. However, the Haut Conseil de la Sante´ Publique (High
Council for Public Health) recommends that all means be
deployed to reach high vaccination coverage, particularly in
young women living in socioeconomic conditions at risk for not
benefitting from optimal conditions of regular cervical cancer
screening. Nonetheless, for the above-mentioned reasons,
vaccination should in no case substitute for screening. The HAS
has also specified that within a few years it would be necessary
to redefine the screening methods for young vaccinated women.
The fight against uterine cervical cancer can only be
conceived as part of an overall strategy integrating both primary
prevention by prophylactic vaccination and screening. Reflec-
tion on vaccination as a whole must therefore be engaged so as
to improve vaccination coverage as wells as screening for
vaccinated women.
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